⌕
Erasca · ERAS · Nasdaq
Tenet 50 · Mixed
Compare
$15.11−3.51%At closeTenet 50 · Mixed
$15.11−0.55 (−3.51%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Erasca (ERAS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 16, 2026 · 08:01 ETCOMPANY'S OWN WORDS
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAP…

● GlobeNewsWireNov 12, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Erasca Reports Third Quarter 2026 Business Updates and Financial Results

ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015 monotherapy and nonc…

● PRNewsWireNov 12, 2026 · 10:05 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at ne…

● PRNewsWireNov 5, 2026 · 19:42 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS).  Such investors are advised to contact Danielle Peyton at ne…

● GlobeNewsWireNov 4, 2026 · 08:30 ET
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the …

● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Erasca to Present at Upcoming Conferences in November

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAP…

● PRNewsWireOct 29, 2026 · 09:45 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS).  Such investors are advised to contact Danielle Peyton at n…

● Business WireOct 23, 2026 · 16:09 ET
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law.…

● PRNewsWireOct 22, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at ne…

● Defense WorldOct 18, 2026 · 02:21 ET
Erasca (NASDAQ:ERAS) Shares Down 5.8% – What’s Next?

Shares of Erasca, Inc. (NASDAQ: ERAS - Get Free Report) fell 5.8% on Friday. The stock traded as low as $13.86 and last traded at $14.0050. Approximately 228,699 shares changed hands during mid-day trading, a decline of …

● Globe News WireOct 15, 2026 · 08:30 ET
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ: AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased sha…

● Seeking AlphaOct 5, 2026 · 10:43 ET
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower

Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, s…

● Defense WorldOct 3, 2026 · 04:44 ET
Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09

Erasca, Inc. (NASDAQ: ERAS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated …

● GlobeNewsWireSep 22, 2026 · 12:34 ET
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and off…

● GlobeNewsWireSep 22, 2026 · 08:30 ET
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015 Dataset MELBOURNE, Austral…

● GlobeNewsWireSep 21, 2026 · 09:27 ET
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against certain of its officers and directo…

● Defense WorldSep 17, 2026 · 03:32 ET
Engineers Gate Manager LP Takes Position in Erasca, Inc. $ERAS

Engineers Gate Manager LP bought a new position in Erasca, Inc. (NASDAQ: ERAS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 87,380 shares o…

● GlobeNewsWireSep 16, 2026 · 08:30 ET
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, inclu…

● Seeking AlphaSep 15, 2026 · 17:01 ET
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Globe News WireSep 15, 2026 · 09:07 ET
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS): Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed …

● GlobeNewsWireSep 10, 2026 · 08:00 ET
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 t…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ERAS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.